BG106567A - Purine derivatives - Google Patents

Purine derivatives

Info

Publication number: BG106567A
Authority: BG; Bulgaria
Prior art keywords: compounds; purine derivatives; preparation; adenosine; solvates
Prior art date: 1999-10-14

Application number

BG106567A

Other languages

Bulgarian (bg)

English (en)

Inventor

Sandra MONAGHAN

Original Assignee

Pfizer Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-14

Filing date

2002-04-02

Publication date

2002-12-29

2002-04-02 Application filed by Pfizer Inc. filed Critical Pfizer Inc.

2002-12-29 Publication of BG106567A publication Critical patent/BG106567A/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Diabetes (AREA)
Biochemistry (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Gynecology & Obstetrics (AREA)
Reproductive Health (AREA)
Otolaryngology (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Obesity (AREA)

BG106567A 1999-10-14 2002-04-02 Purine derivatives BG106567A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9924361.0A GB9924361D0 (en)	1999-10-14	1999-10-14	Purine derivatives
PCT/IB2000/001446 WO2001027131A1 (fr)	1999-10-14	2000-10-06	Derives de la purine

Publications (1)

Publication Number	Publication Date
BG106567A true BG106567A (en)	2002-12-29

Family

ID=10862758

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG106567A BG106567A (en)	1999-10-14	2002-04-02	Purine derivatives

Country Status (43)

Country	Link
US (1)	US6448236B1 (fr)
EP (1)	EP1220862B1 (fr)
JP (1)	JP3994008B2 (fr)
KR (1)	KR20030022758A (fr)
CN (1)	CN1166678C (fr)
AP (1)	AP2002002480A0 (fr)
AR (1)	AR026052A1 (fr)
AT (1)	ATE321065T1 (fr)
AU (1)	AU771531B2 (fr)
BG (1)	BG106567A (fr)
BR (1)	BR0014760A (fr)
CA (1)	CA2387533C (fr)
CO (1)	CO5261621A1 (fr)
CR (1)	CR6607A (fr)
CZ (1)	CZ20021179A3 (fr)
DE (1)	DE60026861T2 (fr)
EA (1)	EA004985B1 (fr)
EC (1)	ECSP003713A (fr)
EE (1)	EE200200194A (fr)
ES (1)	ES2257317T3 (fr)
GB (1)	GB9924361D0 (fr)
GE (1)	GEP20043324B (fr)
GT (2)	GT200000170A (fr)
HK (1)	HK1047942B (fr)
HR (1)	HRP20020325A2 (fr)
HU (1)	HUP0203485A3 (fr)
IL (1)	IL148331A0 (fr)
IS (1)	IS6287A (fr)
MA (1)	MA26829A1 (fr)
MX (1)	MXPA02003750A (fr)
MY (1)	MY141512A (fr)
NO (1)	NO20021751L (fr)
NZ (1)	NZ517294A (fr)
OA (1)	OA12060A (fr)
PA (1)	PA8503601A1 (fr)
PE (1)	PE20010753A1 (fr)
PL (1)	PL354880A1 (fr)
SK (1)	SK4742002A3 (fr)
SV (1)	SV2002000199A (fr)
TN (1)	TNSN00203A1 (fr)
TR (1)	TR200201001T2 (fr)
WO (1)	WO2001027131A1 (fr)
ZA (1)	ZA200202725B (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0003960D0 (en)	2000-02-18	2000-04-12	Pfizer Ltd	Purine derivatives
GB0015727D0 (en) *	2000-06-27	2000-08-16	Pfizer Ltd	Purine derivatives
US6921753B2 (en)	2000-06-27	2005-07-26	Pfizer Inc	Purine derivatives
GB0022695D0 (en)	2000-09-15	2000-11-01	Pfizer Ltd	Purine Derivatives
AR044519A1 (es)	2003-05-02	2005-09-14	Novartis Ag	Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
US20050033044A1 (en)	2003-05-19	2005-02-10	Bristol-Myers Squibb Pharma Company	Methods for preparing 2-alkynyladenosine derivatives
GB0401334D0 (en)	2004-01-21	2004-02-25	Novartis Ag	Organic compounds
EP1728793B1 (fr)	2004-03-26	2016-02-03	Sumitomo Dainippon Pharma Co., Ltd.	Compose 8-oxoadenine 9-substitue
TWI346109B (en)	2004-04-30	2011-08-01	Otsuka Pharma Co Ltd	4-amino-5-cyanopyrimidine derivatives
GB0411056D0 (en)	2004-05-18	2004-06-23	Novartis Ag	Organic compounds
EP2221307A1 (fr)	2004-05-26	2010-08-25	Inotek Pharmaceuticals Corporation	Derivés de purines agonistes du récepteur adénosine A1 et leur utilisation
NZ554506A (en) *	2004-09-20	2011-01-28	Inotek Pharmaceuticals Corp	Purine derivatives and methods of use thereof
GB0424284D0 (en)	2004-11-02	2004-12-01	Novartis Ag	Organic compounds
GB0426164D0 (en)	2004-11-29	2004-12-29	Novartis Ag	Organic compounds
GB0510390D0 (en)	2005-05-20	2005-06-29	Novartis Ag	Organic compounds
EP1957530A2 (fr)	2005-10-21	2008-08-20	Novartis AG	Anticorps humains contre l'il-13 et ses utilisations therapeutiques
US7732424B2 (en) *	2005-11-30	2010-06-08	Inotek Pharmaceuticals Corporation	Purine derivatives and methods of use thereof
GB0601951D0 (en)	2006-01-31	2006-03-15	Novartis Ag	Organic compounds
PT2013211E (pt) *	2006-04-21	2012-06-21	Novartis Ag	Derivados de purina para utilização como agonistas de receptores a2a de adenosina
WO2008004948A1 (fr)	2006-07-05	2008-01-10	Astrazeneca Ab	Dérivés de la 8-oxoadénine agissant comme modulateurs de tlr7
EP2081933B1 (fr)	2006-09-29	2011-03-23	Novartis AG	PYRAZOLOPYRIMIDINES UTILISÉES COMME INHIBITEURS DES LIPIDES KINASES Pl3K
MX2009004715A (es)	2006-10-30	2009-05-20	Novartis Ag	Compuestos heterociclicos como agentes antiinflamatorios.
TW200831105A (en) *	2006-12-14	2008-08-01	Astrazeneca Ab	Novel compounds
US20100105652A1 (en) *	2007-03-02	2010-04-29	Glaxo Group Limited	Purines as cysteine protease inhibitors
PT2132209E (pt) *	2007-03-19	2014-04-15	Astrazeneca Ab	Compostos de 8-oxo-adenina substituídos na posição 9, como moduladores do recetor de tipo ¿toll¿ (tlr7)
US8063051B2 (en) *	2007-03-19	2011-11-22	Astrazeneca Ab	9-substituted-8-oxo-adenine compounds as toll-like receptor (TLR7) modulators
US8044056B2 (en)	2007-03-20	2011-10-25	Dainippon Sumitomo Pharma Co., Ltd.	Adenine compound
PE20081887A1 (es) *	2007-03-20	2009-01-16	Dainippon Sumitomo Pharma Co	Nuevo compuesto de adenina
MY150519A (en) *	2007-05-08	2014-01-30	Astrazeneca Ab	Imidazoquinolines with immuno-modulating properties
UY31531A1 (es)	2007-12-17	2009-08-03		Sales derivadas de 8-oxoadenina composiciones farmacéuticas que las contienen y su uso en terapia como moduladores de receptor tipo toll (tlr)
JP5584138B2 (ja)	2008-01-11	2014-09-03	ノバルティスアーゲー	キナーゼ阻害剤としてのピリミジン類
WO2009091031A1 (fr) *	2008-01-17	2009-07-23	Dainippon Sumitomo Pharma Co., Ltd.	Procédé de production d'un composé d'adénine
WO2009091032A1 (fr)	2008-01-17	2009-07-23	Dainippon Sumitomo Pharma Co., Ltd.	Procédé de production d'un composé d'adénine
US20110281917A1 (en)	2009-01-29	2011-11-17	Darrin Stuart	Substituted Benzimidazoles for the Treatment of Astrocytomas
US8389526B2 (en)	2009-08-07	2013-03-05	Novartis Ag	3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru)	2009-08-12	2012-09-28	Новартис Аг	Гетероциклические гидразоны и их применение для лечения рака и воспаления
AU2010284254B2 (en)	2009-08-17	2015-09-17	Intellikine, Llc	Heterocyclic compounds and uses thereof
EA201200318A1 (ru)	2009-08-20	2012-09-28	Новартис Аг	Гетероциклические оксимы
JP2013512859A (ja) *	2009-12-03	2013-04-18	大日本住友製薬株式会社	トール様受容体（ｔｌｒ）を介して作用するイミダゾキノリン
SI2523669T1 (sl)	2010-01-11	2017-05-31	Inotek Pharmaceuticals Corporation	Kombinacija, komplet in metoda za zmanjšanje intraokularnega tlaka
SG184221A1 (en)	2010-03-26	2012-10-30	Inotek Pharmaceuticals Corp	Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof
UY33597A (es)	2010-09-09	2012-04-30	Irm Llc	Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (fr)	2010-09-09	2012-03-15	Irm Llc	Composés et compositions comme inhibiteurs de trk
ES2575688T3 (es)	2010-12-16	2016-06-30	Sumitomo Dainippon Pharma Co., Ltd.	Derivado de imidazo[4,5-c]quinolin-1-ilo útil en terapia
JP5978226B2 (ja)	2010-12-17	2016-08-24	大日本住友製薬株式会社	プリン誘導体
US20130324526A1 (en)	2011-02-10	2013-12-05	Novartis Ag	[1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (fr)	2011-02-23	2012-08-30	Intellikine, Llc	Composés hétérocycliques et leurs utilisations
AU2012220572A1 (en)	2011-02-25	2013-08-29	Irm Llc	Compounds and compositions as trk inhibitors
EA026655B1 (ru)	2011-09-15	2017-05-31	Новартис Аг	6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
JP6130391B2 (ja)	2011-11-23	2017-05-17	インテリカイン，エルエルシー	Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
SG11201403979TA (en)	2012-01-26	2014-08-28	Inotek Pharmaceuticals Corp	Anhydrous polymorphs of (2r,3s,4r,5r)-5-(6-(cyclopentylamino)-9h-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl) } methyl nitrate and processes of preparation thereof
US20150297604A1 (en)	2012-04-03	2015-10-22	Novartis Ag	Combination Products with Tyrosine Kinase Inhibitors and their Use
CN105246482A (zh)	2013-03-15	2016-01-13	因特利凯有限责任公司	激酶抑制剂的组合及其用途
SG11201506882YA (en)	2013-03-15	2015-09-29	Inotek Pharmaceuticals Corp	Ophthalmic formulations
TW201605450A (zh)	2013-12-03	2016-02-16	諾華公司	Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
WO2016011658A1 (fr)	2014-07-25	2016-01-28	Novartis Ag	Polythérapie
JP6526789B2 (ja)	2014-07-31	2019-06-05	ノバルティスアーゲー	組み合わせ療法
CA3102279A1 (fr)	2018-06-01	2019-12-05	Cornell University	Polytherapie pour maladie ou trouble associe a pi3k
TW202140550A (zh)	2020-01-29	2021-11-01	瑞士商諾華公司	使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5536419A (en) *	1978-09-08	1980-03-14	Yamasa Shoyu Co Ltd	2-substituted adenosine derivative and its preparation
AU8276187A (en) *	1986-10-31	1988-05-25	Warner-Lambert Company	Selected n6-substituted adenosines having selective a2 binding activity
KR0166088B1 (ko)	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en)	1990-01-23	1994-12-27	University Of Kansas	Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5877180A (en) *	1994-07-11	1999-03-02	University Of Virginia Patent Foundation	Method for treating inflammatory diseases with A2a adenosine receptor agonists
GB9414193D0 (en)	1994-07-14	1994-08-31	Glaxo Group Ltd	Compounds
GB9711643D0 (en)	1997-06-05	1997-07-30	Janssen Pharmaceutica Nv	Glass thermoplastic systems
BR9914526A (pt) *	1998-10-16	2001-07-03	Pfizer	Derivados de adenina
GB9913932D0 (en)	1999-06-15	1999-08-18	Pfizer Ltd	Purine derivatives

1999
- 1999-10-14 GB GBGB9924361.0A patent/GB9924361D0/en not_active Ceased
2000
- 2000-09-26 PA PA20008503601A patent/PA8503601A1/es unknown
- 2000-10-06 SK SK474-2002A patent/SK4742002A3/sk unknown
- 2000-10-06 ES ES00962773T patent/ES2257317T3/es not_active Expired - Lifetime
- 2000-10-06 JP JP2001530349A patent/JP3994008B2/ja not_active Expired - Fee Related
- 2000-10-06 GE GE4727A patent/GEP20043324B/en unknown
- 2000-10-06 WO PCT/IB2000/001446 patent/WO2001027131A1/fr not_active Ceased
- 2000-10-06 HR HR20020325A patent/HRP20020325A2/xx not_active Application Discontinuation
- 2000-10-06 OA OA1200200103A patent/OA12060A/en unknown
- 2000-10-06 AU AU74412/00A patent/AU771531B2/en not_active Ceased
- 2000-10-06 HK HK03100163.8A patent/HK1047942B/zh not_active IP Right Cessation
- 2000-10-06 AP APAP/P/2002/002480A patent/AP2002002480A0/en unknown
- 2000-10-06 IL IL14833100A patent/IL148331A0/xx unknown
- 2000-10-06 CZ CZ20021179A patent/CZ20021179A3/cs unknown
- 2000-10-06 AT AT00962773T patent/ATE321065T1/de not_active IP Right Cessation
- 2000-10-06 TR TR2002/01001T patent/TR200201001T2/xx unknown
- 2000-10-06 EP EP00962773A patent/EP1220862B1/fr not_active Expired - Lifetime
- 2000-10-06 BR BR0014760-5A patent/BR0014760A/pt not_active IP Right Cessation
- 2000-10-06 DE DE60026861T patent/DE60026861T2/de not_active Expired - Fee Related
- 2000-10-06 CN CNB008141762A patent/CN1166678C/zh not_active Expired - Fee Related
- 2000-10-06 NZ NZ517294A patent/NZ517294A/en unknown
- 2000-10-06 MX MXPA02003750A patent/MXPA02003750A/es active IP Right Grant
- 2000-10-06 KR KR1020027004766A patent/KR20030022758A/ko not_active Abandoned
- 2000-10-06 EE EEP200200194A patent/EE200200194A/xx unknown
- 2000-10-06 PL PL00354880A patent/PL354880A1/xx not_active Application Discontinuation
- 2000-10-06 CA CA002387533A patent/CA2387533C/fr not_active Expired - Fee Related
- 2000-10-06 HU HU0203485A patent/HUP0203485A3/hu unknown
- 2000-10-06 EA EA200200360A patent/EA004985B1/ru not_active IP Right Cessation
- 2000-10-10 GT GT200000170A patent/GT200000170A/es unknown
- 2000-10-12 MY MYPI20004789A patent/MY141512A/en unknown
- 2000-10-12 GT GT200000173A patent/GT200000173A/es unknown
- 2000-10-12 CO CO00077983A patent/CO5261621A1/es not_active Application Discontinuation
- 2000-10-12 EC EC2000003713A patent/ECSP003713A/es unknown
- 2000-10-13 AR ARP000105422A patent/AR026052A1/es unknown
- 2000-10-13 SV SV2000000199A patent/SV2002000199A/es unknown
- 2000-10-13 PE PE2000001099A patent/PE20010753A1/es not_active Application Discontinuation
- 2000-10-13 TN TNTNSN00203A patent/TNSN00203A1/fr unknown
- 2000-10-16 US US09/688,497 patent/US6448236B1/en not_active Expired - Fee Related
2002
- 2002-02-26 IS IS6287A patent/IS6287A/is unknown
- 2002-03-11 CR CR6607A patent/CR6607A/es not_active Application Discontinuation
- 2002-04-02 BG BG106567A patent/BG106567A/xx unknown
- 2002-04-08 ZA ZA200202725A patent/ZA200202725B/en unknown
- 2002-04-09 MA MA26591A patent/MA26829A1/fr unknown
- 2002-04-12 NO NO20021751A patent/NO20021751L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
HK1047942A1 (zh)	2003-03-14
TNSN00203A1 (fr)	2002-05-30
GB9924361D0 (en)	1999-12-15
CZ20021179A3 (cs)	2003-04-16
JP2003511460A (ja)	2003-03-25
AR026052A1 (es)	2002-12-26
CN1378551A (zh)	2002-11-06
MXPA02003750A (es)	2003-10-14
AU771531B2 (en)	2004-03-25
PE20010753A1 (es)	2001-07-17
CO5261621A1 (es)	2003-03-31
MA26829A1 (fr)	2004-12-20
CN1166678C (zh)	2004-09-15
NO20021751D0 (no)	2002-04-12
GEP20043324B (en)	2004-04-13
GT200000170A (es)	2002-04-03
EA200200360A1 (ru)	2002-10-31
HUP0203485A2 (hu)	2003-03-28
CA2387533C (fr)	2007-03-13
AP2002002480A0 (en)	2002-06-30
CA2387533A1 (fr)	2001-04-19
KR20030022758A (ko)	2003-03-17
JP3994008B2 (ja)	2007-10-17
EE200200194A (et)	2003-06-16
HRP20020325A2 (en)	2004-04-30
WO2001027131A1 (fr)	2001-04-19
DE60026861T2 (de)	2006-09-21
IS6287A (is)	2002-02-26
EP1220862A1 (fr)	2002-07-10
BR0014760A (pt)	2002-07-02
SK4742002A3 (en)	2003-05-02
HUP0203485A3 (en)	2005-02-28
AU7441200A (en)	2001-04-23
EA004985B1 (ru)	2004-10-28
ES2257317T3 (es)	2006-08-01
ATE321065T1 (de)	2006-04-15
ECSP003713A (es)	2002-05-23
MY141512A (en)	2010-05-14
PL354880A1 (en)	2004-03-22
EP1220862B1 (fr)	2006-03-22
US6448236B1 (en)	2002-09-10
DE60026861D1 (de)	2006-05-11
SV2002000199A (es)	2002-02-05
OA12060A (en)	2006-05-03
HK1047942B (zh)	2005-04-01
IL148331A0 (en)	2002-09-12
ZA200202725B (en)	2003-04-08
GT200000173A (es)	2002-04-05
NO20021751L (no)	2002-06-13
PA8503601A1 (es)	2002-02-21
TR200201001T2 (tr)	2002-09-23
NZ517294A (en)	2004-03-26
CR6607A (es)	2003-11-25

Publication	Publication Date	Title
BG106567A (en)	2002-12-29	Purine derivatives
BG106289A (en)	2002-09-30	Purine derivatives
MY136242A (en)	2008-08-29	Purine derivatives
BG107171A (en)	2003-07-31	Purine derivatives
BG106906A (en)	2003-04-30	Purine derivatives
AP2001002287A0 (en)	2001-12-31	Purine derivatives.
AU5879299A (en)	2000-05-08	Adenine derivatives
MXPA02012033A (es)	2003-04-25	Derivados de 2-aminocarbonil-9h-purina.
HRP20031003A2 (en)	2004-06-30	4'-substituted nukleosides
IL150986A0 (en)	2003-02-12	1,2,3,4,- tetrahydroisoquinoline derivatives
IL159880A0 (en)	2004-06-20	Arylsulfonyl derivatives with 5-ht6 receptor affinity
GEP20094697B (en)	2009-06-10	Condensed purine derivatives as a1 adenosine receptor antagonists
TW360652B (en)	1999-06-11	Acryloyl substituted disstamycin derivatives, process for preparing them, and pharmaceutical composition comprising them
YU82302A (sh)	2005-11-28	Derivati 2-aminokarbonil-9h-purina